Selected category: "Regulatory Affairs News" 
On July 20, the CDE of China's NMPA released the guidelines for the submission of drug clinical trial data..
All chemical and biological products be governed by these new guidelines starting on October 1, 2020, as part of China's wider eCTD implementation following the release of M4 module 1 document.
This entry was posted in Regional News, Regulatory Affairs News.
The Center of Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has issued the “M4 Module 1: Administration documents and drug information”, which took effect on July 1, 2020.
This is the result of the activities the NMPA began in April 2020, when they started to solicit public comments on the draft version of several documents. For more details on this, have a look at our previous blog post.
This entry was posted in Regional News, Regulatory Affairs News.
Update on eCTD submissions in China
Posted on May 18, 2020
Before the final release of the supporting documents for the "Measures for the administration of drug registration", the China NMPA has issued the following drafts for public consultation:
- "Chemical drug registration classification and requirements for submission materials",
- "Variations and requirements for submission materials of marketed chemical drugs",
- "Technical guidelines for CMC variations research of marketed chemical drugs",
- "Guidelines for the acceptance and review of chemical drug registration",
- "Guidelines for acceptance and review of CMC variations of chemical changes".
This entry was posted in Regional News, Regulatory Affairs News.
eValidator profile available for Canadian XML Product Monograph pilot
Posted on April 28, 2020
In January, Health Canada notified industry of their plans and timelines to start transitioning product monograph templates into a structured format based on XML, HL7 Structured Product Label (SPL) standard and controlled vocabularies.
This entry was posted in LORENZ Solutions and Services, Regional News, Regulatory Affairs News.
Electronic submissions in the EAEU – publishing module available for interested LORENZ customers
Posted on February 13, 2020
LORENZ has implemented a publishing module for EAEU submissions in docuBridge based on the EECB No. 79 specifications and the R.022 schema. Interested customers can connect to LORENZ Cloud for an early glimpse on how to publish EAEU submissions. Please contact your Account Manager for further information. The publishing module will be continually updated to reflect any further specification changes. The EAEU submission publishing will soon be commercially available as a normal docuBridge publishing module.
This entry was posted in Regional News, Regulatory Affairs News.
Update on eCTD submissions in China: Chinese CDE conducted eCTD Pilot
Posted on January 15, 2020
The CDE, China's regulatory agency conducted an eCTD pilot from November 25th through December 4th 2019. A selected number of industry companies were nominated to submit electronic submissions in eCTD format (CN v1.0 DRAFT).
This entry was posted in Regional News, Regulatory Affairs News.
eCTD submissions in China: CDE is now soliciting opinions on eCTD submission guidelines
Posted on September 26, 2019
On September 17, 2019, the official website of the CDE of the Chinese NMPA began soliciting public opinions on the preliminary draft of eCTD submission guidelines, the supporting eCTD technical specifications, verification standards and other related documents. The deadline for submitting opinions is October 17, 2019. Please provide your feedback before this closing date.
This entry was posted in Regional News, Regulatory Affairs News.
Updates on the HMA eSubmission Roadmap
Posted on August 7, 2019
The eSubmission Roadmap v2.2 has recently been updated by the HMA. The purpose of the roadmap is to provide a high level strategic plan for business and technology changes over several years, and is meant to help NCAs, EMA and pharmaceutical industry prepare themselves for the forthcoming changes. Many of the adjustments are likely due to the EMA's relocation.
Compared to the version 2.1 of the roadmap, the most important changes are
This entry was posted in Regulatory Affairs News.